Cornerstone Capital Inc. Takes $459,000 Position in Nephros Inc. $NEPH

Cornerstone Capital Inc. bought a new position in shares of Nephros Inc. (NASDAQ:NEPH) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 128,700 shares of the company’s stock, valued at approximately $459,000. Cornerstone Capital Inc. owned 1.19% of Nephros as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NEPH. Geode Capital Management LLC lifted its stake in shares of Nephros by 3.2% in the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after buying an additional 2,898 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of Nephros by 7.2% during the fourth quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock valued at $291,000 after buying an additional 4,000 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Nephros by 39.2% during the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Nephros during the fourth quarter worth about $29,000. Finally, XTX Topco Ltd raised its holdings in shares of Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after acquiring an additional 7,062 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors.

Nephros Price Performance

NEPH opened at $4.63 on Friday. Nephros Inc. has a 1 year low of $2.66 and a 1 year high of $6.42. The company has a market capitalization of $50.28 million, a price-to-earnings ratio of 28.94 and a beta of 1.51. The firm’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $3.52.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter. Nephros had a net margin of 8.38% and a return on equity of 10.60%. The company had revenue of $6.02 million during the quarter, compared to the consensus estimate of $4.99 million. As a group, equities analysts anticipate that Nephros Inc. will post 0.03 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on NEPH shares. Zacks Research raised shares of Nephros to a “hold” rating in a research report on Monday, July 20th. Northland Securities initiated coverage on Nephros in a research note on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective for the company. Finally, Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.